Document is current

Article History

Received: 16 July 2024

Accepted: 10 October 2024

First Online: 5 November 2024

Declarations

:

: Bradley J. Monk reports consulting fees from Acrivon, Adaptimune, Agenus, Akeso Bio, Amgen, Aravive, AstraZeneca, Bayer, Clovis, Eisai, Elevar, EMD Merck, Genmab/Seagen, GOG Foundation, Gradalis, Heng Rui, ImmunoGen, Karyopharm, Iovance, Laekna, Macrogenics, Merck, Mersana, Myriad, Novartis, Novocure, OncoC4, Panavance, Pieris, Pfizer, Puma, Regeneron, Roche/Genentech, Sorrento, TESARO/GSK, US Oncology Research, VBL, Verastem, and Zentalis; and payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from AstraZeneca, Eisai, Myriad, Roche/Genentech, and TESARO/GSK. Sophie van Mens, Oliver Hale, Jennifer Boer, and Frank van Hees were employees of Lumanity at the time the analysis was performed. Lumanity conducted the cost-effectiveness analysis and carried out the writing of the manuscript on behalf of MSD. Lumanity was paid by MSD as an external consultant to conduct this work. Sophie van Mens is now an employee at PharmAccess. Oliver Hale is now an employee at Delta Hat Limited. Jennifer Boer is now an employee at Equalis Strategy & Modeling BV. Frank van Hees is now an employee at Maple Health Group, LLC. Shilpi Swami was an employee of MSD (UK) Ltd., London, UK at the time the analysis was performed, who may own stock and/or stock options in Merck & Co., Inc., Rahway, NJ, USA. Dominic Muston, Cumhur Tekin, Steve Keefe, and Matthew Monberg are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, who may own stock and/or stock options in Merck & Co., Inc., Rahway, NJ, USA.

: This study was based on previously collected, anonymized clinical trial data from KEYNOTE-826 provided by the study sponsor; as such, it was exempt from institutional review board or ethical approval. The KEYNOTE-826 trial was approved by the appropriate ethics body at each participating center [, ].